Delving into the Latest Updates on Suzhou Landing Biopharmaceutical, Inc. with Synapse

Overview

Tags

Cardiovascular Diseases

Recombinant polypeptide

Biosimilar

Enzyme

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Recombinant polypeptide	1
Biosimilar	1
Enzyme	1

Top 5 Target	Count

NPRA(Natriuretic peptide receptor 1)	1
PLG(Plasminogen)	1

On the basis of Phase I and Phase II clinical studies, rt-PA was used as a positive control drug to further evaluate the effectiveness and safety of intravenous thrombolysis for the treatment of acute ST-segment elevation myocardial infarction in patients with body weight ≤ 85KG using 6 million IU/case of recombinant human urokinase developed by Suzhou Landing Biopharmaceuticals Co., Ltd.

Start Date28 Jan 2015

Sponsor / Collaborator

Suzhou Landing Biopharmaceutical, Inc.

CTR20260238

/ Not yet recruitingPhase 3

一项评价注射用重组人尿激酶原（rhProuk）治疗急性ST段抬高型心肌梗死（STEMI）的疗效和安全性---多中心、随机、单盲、阿替普酶阳性对照的Ⅲ期临床研究

[Translation] A multicenter, randomized, single-blind, alteplase-positive controlled phase III clinical trial evaluating the efficacy and safety of recombinant human prourokinase (rhProuk) for injection in the treatment of acute ST-segment elevation myocardial infarction (STEMI).

主要目的：以阿替普酶为阳性对照药，评估注射用重组人尿激酶原（rhProuk）治疗急性ST段抬高型心肌梗死（STEMI）的有效性。次要目的：以阿替普酶为阳性对照药，评估注射用重组人尿激酶原（rhProuk）治疗急性ST段抬高型心肌梗死（STEMI）的安全性及临床开通率。 (1)按照临床指标判断的给予溶栓药物后的梗死相关动脉再通率； (2)溶栓后30天内的临床MACCE事件发生率； (3)出血性事件发生率。

[Translation]

Primary objective: To evaluate the efficacy of recombinant human prourokinase (rhProuk) for injection in the treatment of acute ST-segment elevation myocardial infarction (STEMI), using alteplase as a positive control. Secondary objective: To evaluate the safety and clinical recanalization rate of recombinant human prourokinase (rhProuk) for injection in the treatment of acute ST-segment elevation myocardial infarction (STEMI), using alteplase as a positive control. (1) Recanalization rate of the infarct-related artery after administration of thrombolytic drugs, as determined by clinical indicators; (2) Incidence of clinical MACCE events within 30 days after thrombolysis; (3) Incidence of hemorrhagic events.

Start Date-

Sponsor / Collaborator

Suzhou Landing Biopharmaceutical, Inc.

100 Clinical Results associated with Suzhou Landing Biopharmaceutical, Inc.

Login to view more data

0 Patents (Medical) associated with Suzhou Landing Biopharmaceutical, Inc.

Login to view more data

100 Deals associated with Suzhou Landing Biopharmaceutical, Inc.

Login to view more data

100 Translational Medicine associated with Suzhou Landing Biopharmaceutical, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human brain natriuretic peptide (RxD Biopharma) ( NPRA )	Heart Failure More	Approved
Recombinant human prourokinase(Suzhou RxD Biopharmaceutical Co., Ltd) ( PLG )	ST Elevation Myocardial Infarction More	Phase 3